Company
Medical research institute whose Tumour Immunology Laboratory developed the vaccine candidate and spawned the spin-out
Every investor coverage indicates participated in a round QIMR Berghofer raised.
Companies QIMR Berghofer acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Associate Professor Daniel Rawle | Associate Professor | Mirage News |
Stories naming QIMR Berghofer. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UQ spinout Proboxis Biotechnology has received $1.5 million via the first round of the Biointelect Venturer incubator to advance a vaccine platform against mosquito-borne diseases toward human clinical development.
QIMR Berghofer's Ebivanta Therapeutics wins $1.5 million plus backing from biotech incubator Biointelect Venturer's first cohort to ready its mRNA vaccine against Epstein-Barr virus for clinical testing.
CSIRO's ON Accelerate program presents its ninth intake of eleven research startups, drawn from universities nationwide and the agency itself, spanning biotech, healthcare and sustainability, at a Melbourne showcase.
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.